Drugs / 11C-5-HTP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02689479 | May 2013 → Sep 2014 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [(11)C]5-HTP | “We investigated the potential of the endocrine positron emission tomography (PET) marker [(11)C]5-hydroxytryptophan ([(11)C]5-HTP) for this purpose.” PMID 27325286 ↗ Jun 2016 |
| Known as | [(11)C]5-hydroxytryptophan | “We investigated the potential of the endocrine positron emission tomography (PET) marker [(11)C]5-hydroxytryptophan ([(11)C]5-HTP) for this purpose.” PMID 27325286 ↗ Jun 2016 |
| Modality | Diagnostic / imaging agent | “the endocrine positron emission tomography (PET) marker” PMID 27325286 ↗ Jun 2016 |
| Route | Intravenous | “is administered manually as an intravenous bolus” NCT02689479 ↗ |